"The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for"...
In clinical trials using daily subcutaneous injections of leuprolide acetate in patients with prostate cancer, doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.
ELIGARD (leuprolide acetate) ® is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs or any of the components of ELIGARD (leuprolide acetate) ®. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature.
ELIGARD (leuprolide acetate) may cause fetal harm when administered to a pregnant woman. Expected hormonal changes that occur with ELIGARD (leuprolide acetate) treatment increase the risk for pregnancy loss and fetal harm when administered to a pregnant women [see Use in Specific Populations]. ELIGARD (leuprolide acetate) is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Last reviewed on RxList: 3/3/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Eligard Information
Eligard - User Reviews
Eligard User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.